2014Data Archiving and Networked Services (DANS)Open access

Intraepithelial lymphocytes in refractory celiac disease : lost in transition

Frederike Schmitz

Open full text 0 citations

Abstract

Refractory coeliac disease type II (RCDII) is a severe complication of coeliac disease. Whereas celiac disease can successfully be treated by the strict avoidance of gluten, refractory celiac patients show no remission despite a gluten-free diet. The pathology of RCDII is only partially understood, but a key feature of RCDII is the expansion of aberrant CD3- intraepithelial lymphocytes (IEL) in the small intestinal epithelium. Whereas the majority of IEL generally are composed of CD3+ T cells, in RCDII CD3- IEL form 20-80% of the IEL population. In approximately 40% of RCDII patients these lymphocytes develop into a lethal, invasive lymphoma. In this thesis, we identify a potential physiological precursor to the (pre)malignant CD3- IEL found in RCDII patients, and compared the composition, phenotype and differentiation potential of CD3- IEL in non-celiac, celiac as well as refractory celiac disease

Open-access reader

About this research paper

What this paper is about

Refractory coeliac disease type II (RCDII) is a severe complication of coeliac disease. Whereas celiac disease can successfully be treated by the strict avoidance of gluten, refractory celiac patients show no remission despite a gluten-free diet. The pathology of RCDII is only partially understood, but a key feature of RCDII is the expansion of aberrant CD3- intraepithelial lymphocytes (IEL) in the small intestinal epithelium. Whereas the majority of IEL generally are composed of CD3+ T cells, in RCDII CD3- IEL form 20-80% of the IEL population. In approximately 40% of RCDII patients these lymphocytes develop into a lethal, invasive lymphoma. In this thesis, we identify a potential physiological precursor to the (pre)malignant CD3- IEL found in RCDII patients, and compared the composition, phenotype and differentiation potential of CD3- IEL in non-celiac, celiac as well as refractory celiac disease

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Refractory coeliac disease type II (RCDII) is a severe complication of coeliac disease. Whereas celiac disease can successfully be treated by the strict avoidance of gluten, refractory celiac patients show no remission despite a gluten-free diet. The pathology of RCDII is only partially understood, but a key feature of RCDII is the expansion of aberrant CD3- intraepithelial lymphocytes (IEL) in the small intestinal epithelium. Whereas the majority of IEL generally are composed of CD3+ T cells, in RCDII CD3- IEL form 20-80% of the IEL population. In approximately 40% of RCDII patients these lymphocytes develop into a lethal, invasive lymphoma. In this thesis, we identify a potential physiological precursor to the (pre)malignant CD3- IEL found in RCDII patients, and compared the composition, phenotype and differentiation potential of CD3- IEL in non-celiac, celiac as well as refractory celiac disease

Key concepts: Intraepithelial lymphocyte, Coeliac disease, Gluten free, Refractory (planetary science), CD3, Population, Medicine, Disease

Related papers

Back to paper searchBrowse research topicsOriginal source
Intraepithelial lymphocytes in refractory celiac disease : lost in transition — Research Paper | ScholarLens